Does curcumin have an effect on sleep duration in metabolic syndrome patients?

Maryam Saberi-Karimian¹,², Hamideh Ghazizadeh¹,⁵, Elham Mohammadzadeh⁵,⁶, Gordon A. Ferns², Majid Ghayour-Mobarhan¹,³,†, Amirhosein Sahebkar⁴,†

¹International UNESCO center for Health Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran
²Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK
³Cardiovascular Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
⁴Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
⁵Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
⁶Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Article history:
Received: Jun 27, 2018
Received in revised form: Feb 17, 2019
Accepted: Mar 10, 2019
Vol. 11, No. 2, Mar-Apr 2021, 190-198.

† Equal Corresponding Author:
Tel: +985138002288
Fax: +985138002287
ghayourm@mums.ac.ir
sahebkara@mums.ac.ir

Keywords:
Curcumin
Sleep duration
Metabolic syndrome

Abstract

Objective: Sleep-duration is related to obesity. Curcumin can affect behavioral changes that arise from sleep deprivation in animal models. In this study, we assessed the effects of curcumin on sleep-duration in metabolic syndrome (MetS) patients.

Materials and Methods: This study was a double-blind clinical trial in 120 adults with MetS. All participants received crude curcuminoids in a simple formulation (n=40), phospholipidated curcuminoids (n=40) or placebo (n=40) 1 g/day during 6 weeks. Demographic data, anthropometric indices and serum biochemical factors were documented for all volunteers at baseline and after the intervention. A standard questionnaire was used for evaluating physical-activity-level (PAL) and patients’ sleep-duration, including night time sleep and daily napping. Based on the time of sleep, sleeping hours were classified into: night time sleep; daily naps and total sleeping hours in 24 hours.

Results: A total of 120 participants aged 38.72±10.05 years old were enrolled into the study. We did not find significant differences in biochemical factors, sleep-duration or PAL at baseline among the 3 groups (p>0.05). Moreover, curcumin did not exert any significant effect on sleep-duration before, or after, adjustment for confounding factors in the overweight and obese individuals, or in total population (p>0.05).

Conclusion: The results showed that curcumin does not have an effect on sleep-duration in subject with MetS.

Introduction

Metabolic syndrome (MetS) is a multifaceted disorder with a cluster of cardiovascular disease (CVD) risk factors including abdominal obesity, hyperglycemia, hypertriglyceridemia,
hypertension and decreased high-density lipoprotein cholesterol (HDL-C) concentrations (Reaven, 1988). The prevalence of MetS has increased globally due to excessive consumption of energy-dense foods a long with sedentary lifestyle. A high prevalence of MetS in Iranian adults has been reported (36.9 and 34.6% respectively based on the Adult Treatment Panel III criteria (ATP III) and the International Diabetes Federation (IDF) criteria). Moreover, the prevalence of MetS was reported to be higher in women compared with men (Amirkalali et al., 2015). Furthermore 6.5% of the Iranian people, and 45% of obese girls have MetS in Mashhad, Khorasan Razavi, Iran (Mirhosseini et al., 2009).

There is a need for adjunctive, or alternative therapies, to reduce the residual CVD risk that remains following taking statin in these individuals, and a lack of tolerability or therapeutic response in certain groups of patients (Mohammadi et al., 2013). It has been suggested that phytochemicals may exert some metabolic and health advantages (Karalis, 2008; Miquel et al., 2002; Panahi et al., 2014a; Panahi et al., 2014b; Sahoo et al., 2008; Visioli and Davalos, 2011; Sahebkar, 2013.). Turmeric is used for the treatment of hepatic disorders, diabetic wounds, rheumatism, biliary disorders, anorexia, and cough (Panahi et al., 2012; Sahebkar, 2011). Curcuminoids are known as the main active components of turmeric, which comprise curcumin (diferuloylmethane), demethoxycurcumin, and bisdemethoxycurcumin (Sahoo et al., 2008). It has been reported that curcuminoids possess a multitude of biological (Franco-Robles et al., 2013; Marshall et al., 2008; Sahebkar et al., 2013; Taheri 2006; Taheri et al., 2004) and pharmacological effects (Kumar and Singh, 2008; Noorafshan et al., 2017a; Riemann et al., 2007; Saberi-Karimian et al., 2018; Zhang et al., 2013) and can be used to treat a variety of human disorders.

Some studies have reported a link between obesity and sleep duration: for example, short sleep duration was shown to be a risk factor for the development of obesity. Several molecular mechanisms have been suggested to explain this effect (Shi et al., 2008). Energy intake and expenditure as well as physical activity level can be affected by sleep duration (Taheri et al., 2004; Taheri, 2006). Other studies have shown contradictory results (Marshall et al., 2008). Inadequate sleep can reduce the volume of hippocampus (Riemann et al., 2007). It is suggested that sleep deprivation may increase the mediators of oxidative stress in some brain areas (Zhang et al., 2013). In rats’ hippocampus, curcumin has been shown to inhibit the structural and behavioral changes under these conditions (Noorafshan et al., 2017a). Moreover, curcumin can limit oxidative damage and behavioral changes due to sleep deprivation in mice (Kumar and Singh, 2008).

It has been reported that short sleep duration is related to overweight and augmented blood pressure in adolescents in Korea, although there was no association with MetS (Lee and Park, 2014). Here, we evaluated the curcumin’s effects on sleep duration in subjects with MetS.

Materials and Methods

Study design

A total of 120 participants (aged 18 to 65 years) with metabolic syndrome were enrolled into this clinical trial. The subjects were blinded to the study groups and were randomly allocated to: Group 1 and 2- the curcumin groups taking curcumin capsules in simple (1 g/day; n=40) or modified formula (1 g/day=200 mg pure curcumin/day; n=40), and Group 3- control group taking a placebo (lactose & starch; n=40) during 6 weeks. The flow chart of the study design has been shown in Figure 1.

Random number tables were used to randomize patients to curcumin and placebo groups (Fleiss, 2011). Inclusion and exclusion criteria were as previously detailed (Lee and Park, 2014). The inclusion criteria were age of 18 to 65 years with a history of MetS based on the IDF guidelines (2010). IDF criteria are waist
circumference more than 94 and 80 (cm) in male and female, respectively, plus any 2 of the following criteria: 1) triglyceride equal or above 150 mg/dl or taking drug for this kind of dyslipidemia. 2) HDL-C less than 40 and 50 mg/dl respectively in males and females or specific treatment for this lipid abnormality. 3) Systolic blood pressure equal or above 130 or diastolic blood pressure) equal or above 85 mmHg or treatment of previously diagnosed hypertension. 4) Fasting plasma glucose equal or above 100 mg/dl or previously diagnosed type 2 diabetes.

Women who were breastfeeding, or pregnant, or individuals with systemic diseases, or those taking any drugs and nutritional supplements during the project period, were excluded.

The current study was a sub-study from another work registered in the Iranian Registry of Clinical Trials (IRCT2014052014521N3) (Saberi-Karimian et al., 2018). The sample size was calculated 35 individuals per group (considering α=0.05 and β=0.02) in the original work based on the serum triglycerides changes levels according to our previous project (Mohammadi et al., 2013).

Demographic data, blood pressure and anthropometric indices were determined at baseline and after 6 weeks. Blood samples were collected after a 12-hour fasting. Complete blood count (CBC) and serum biochemical factors were determined using routine methods.

Figure 1. The flow chart of the study design

**Physical activity level (PAL) and sleep duration**

PAL was calculated using the questionnaire devised by Vasconcellos and Anjos (2003). The subjects were divided into 5 categories based on human energy requirement involved: a) extremely inactive (less than 1.40), b) sedentary (1.40 to 1.69),
Curcumin and sleep duration

c) moderately active (1.70 to 1.99), d) vigorously active (2.00 to 2.40), or e) extremely active (more than 2.40) (James and Schofield 1990).

We used a standard questionnaire (self-declaration form) to assess patients’ sleep duration, including nighttime sleep and daily nap (James and Schofield 1990). According to the time of sleep, sleeping hours were classified into: a. nighttime sleep (sleep duration only in night); b. daily naps; c. total sleeping hours in 24 hours (including nighttime sleep duration plus the duration of daily naps).

Statistical analysis

Data are stated as mean±SD (for normally distributed variables) or median (first and third quartiles) (for non-normally distributed data). We determined the normality of data using the Kolmogorov-Smirnov test. According to data distribution pattern, we used Student’s t-test, Analysis Of Variance (ANOVA), Mann-Whitney U, and Kruskal-Wallis tests to compare data among the groups. We used a general linear model to detect the independent association between sleep duration and physical activity with Curcumin supplementation. A p-value (two-tailed) less than 0.05 was considered statistically significant using SPSS version 16.0 (SPSS Inc. Chicago, IL, USA).

Results

In this study, a population of 120 subjects including 71.1% male and 28.3% female (aged 38.72±10.05 years) was recruited.

Clinical characteristics

The clinical characteristics of the population at baseline are reported in Table 1. Serum biochemical variables, sleep duration and physical activity at baseline did not show a difference among the three study groups (p>0.05).

Changes of clinical and baseline characteristics of the population between baseline and after 6 weeks of intervention in the three study groups are summarized in Table 2. There was no significant difference in any of the variables such as sleep, PAL and BMI between before and after the intervention (Table 2).

| Variables | Curcumin-phospholipid complex (N=40) | Curcumin (N=40) | Placebo (N=40) | p-value |
|-----------|-------------------------------------|-----------------|----------------|---------|
| Age (years) | 40.05±10.48 | 37.52±9.47 | 38.59±10.28 | 0.92 |
| BMI (kg/m²) | 30.66±5.06 | 30.67±3.57 | 31.22±4.67 | 0.53 |
| Sex | | | | |
| Female% (n) | 62.5 (25) | 77.5 (31) | 75.0 (30) | 0.41 |
| Male% (n) | 37.5 (15) | 22.5 (9) | 25.0 (10) | 0.28 |
| FAT% | 34.51±8.07 | 35.42±6.12 | 35.21±7.86 | 0.86 |
| Total sleep (hr) | 5.81±0.93 | 5.69±1.02 | 5.36±1.02 | 0.56 |
| Nightly sleep (hr) | 4.75±1.79 | 5.05±0.91 | 4.76±0.95 | 0.41 |
| Daily nap (hr) | 1.00±1.10 | 0.62±0.74 | 0.67±0.88 | 0.44 |
| Physical activity level (PAL); n(%) | Extremely inactive | 28 (77.8) | 29 (80.6) | 33 (84.6) |
| Sedentary | 6 (16.7) | 5 (13.9) | 5 (12.8) | 0.704 |
| Moderately active | - | - | - | |
| Vigorously active | - | - | - | |
| Extremely active | 2 (5.6) | 2 (5.6) | 1 (2.6) | |

Values are expressed as mean±SD for normally distributed data, and median and interquartile range for non-normally distributed data. Between groups comparisons were made by parametric statistical analysis for normally distributed data and nonparametric test for non-normally distributed data. BMI, body mass index.
Table 2. The effects of curcumin on PAL, nightly sleep, BMI and daily nap in subjects with metabolic syndrome

| Groups                          | Curcumin-phospholipid complex (N=40) | Curcumin (N=40) | Placebo (N=40) | p-value |
|---------------------------------|--------------------------------------|-----------------|----------------|---------|
| **Physical activity level (PAL)** |                                      |                 |                |         |
| Before                          | 1.23 (0.28)                          | 1.22 (0.25)     | 1.23 (0.21)    | 0.72    |
| After                           | 1.51 (0.31)                          | 1.57 (0.37)     | 1.54 (0.31)    | 0.83    |
| Changes at baseline and after 6 weeks intervention | 0.28 (0.14)                          | 0.30 (0.13)     | 0.29 (0.17)    | 0.32    |
| **BMI (kg/m²)**                 |                                      |                 |                |         |
| Before                          | 30.66 (5.06)                         | 30.67 (3.57)    | 31.22±4.67     | 0.54    |
| After                           |                                      |                 | 31.30±4.78     | 0.56    |
| Changes at baseline and after 6 weeks intervention | -0.19 (0.68)                         | -0.30 (0.76)    | -0.10±0.77     | 0.37    |
| **Nightly sleep (hr)**          |                                      |                 |                |         |
| Before                          | 4.75±0.79                            | 5.05±0.91       | 4.76±0.94      | 0.41    |
| After                           | 4.17±1.72                            | 3.87±2.01       | 3.70±1.98      | 0.38    |
| Changes at baseline and after 6 weeks intervention | -0.48±1.42                          | -1.07±2.25      | -0.97±1.96     | 0.63    |
| **Daily nap (hr)**              |                                      |                 |                |         |
| Before                          | 1.00±1.10                            | 0.62±0.74       | 0.67±0.88      | 0.44    |
| After                           | 0.67±0.79                            | 0.60±0.70       | 0.55±0.78      | 0.55    |
| Changes at baseline and after 6 weeks intervention | -0.32±0.94                           | -0.02±0.42      | -0.12±0.60     | 0.71    |
| **Total sleep (hr)**            |                                      |                 |                |         |
| Before                          | 5.81±1.93                            | 5.69±1.02       | 5.36±1.02      | 0.05    |
| After                           | 4.85±1.98                            | 4.47±2.38       | 4.25±2.28      | 0.33    |
| Changes at baseline and after 6 weeks intervention | -0.86±1.93                           | -1.10±2.44      | -1.05±2.37     | 0.88    |

Values are expressed as mean±SD for normally distributed data, and median and interquartile range for non-normally distributed data. Between groups comparisons were made by parametric statistical analysis for normally distributed data and nonparametric test for non-normally distributed data.

Table 3. The effects of curcumin on sleep duration in subjects with metabolic syndrome

| Groups               | Nightly sleep (hr) | B | Confidence interval 95% | p-value |
|----------------------|-------------------|---|-------------------------|---------|
| **BMI<30 (kg/m²)**   |                   |   |                         |         |
| Changes at baseline and after 6 weeks intervention | Curcumin-phospholipid complex (N=40) | 0.72 | -2.06 to 3.51 | 0.58    |
|                     | Curcumin (N=40)   | -3.08 | -7.13 to 0.95 | 0.12    |
|                     | Placebo (N=40)    | Ref.1 |                 |         |
| Changes at baseline and after 6 weeks intervention | Curcumin-phospholipid complex (N=40) | 0.23 | -0.36 to 0.83 | 0.44    |
|                     | Curcumin (N=40)   | -0.35 | -0.95 to 0.25 | 0.24    |
|                     | Placebo (N=40)    | Ref.1 |                 |         |
| **BMI≥30 (kg/m²)**   |                   |   |                         |         |
| Daily nap (hr)       |                   |   |                         |         |
| Changes at baseline and after 6 weeks intervention | Curcumin-phospholipid complex (N=40) | -0.45 | -1.17 to 0.27 | 0.20    |
|                     | Curcumin (N=40)   | 0.19 | -0.84 to 1.24 | 0.69    |
|                     | Placebo (N=40)    | Ref.1 |                 |         |
| Changes at baseline and after 6 weeks intervention | Curcumin-phospholipid complex (N=40) | -0.18 | -0.44 to 0.04 | 0.13    |
|                     | Curcumin (N=40)   | -0.19 | -0.43 to 0.06 | 0.11    |
|                     | Placebo (N=40)    | Ref.1 |                 |         |
| **BMI<30 (kg/m²)**   |                   |   |                         |         |
| Total sleep (hr)     |                   |   |                         |         |
| Changes at baseline and after 6 weeks intervention | Curcumin-phospholipid complex (N=40) | 0.27 | -2.89 to 3.44 | 0.85    |
|                     | Curcumin (N=40)   | -2.88 | -7.48 to 1.70 | 0.20    |
|                     | Placebo (N=40)    | Ref.1 |                 |         |
| **BMI≥30 (kg/m²)**   |                   |   |                         |         |
| Changes at baseline and after 6 weeks intervention | Curcumin-phospholipid complex (N=40) | 0.04 | -0.69 to 0.78 | 0.90    |
|                     | Curcumin (N=40)   | -0.55 | -1.29 to 0.18 | 0.14    |
|                     | Placebo (N=40)    | Ref.1 |                 |         |

General Linear Model was used after adjusting for changes in the neutrophils, and serum lipoprotein (a) and adiponectin (26) at baseline and after 6 weeks intervention. Values are expressed as mean±SD for normally distributed data. Between groups comparisons were made by parametric statistical analysis for normally distributed data. BMI; body mass index.
Curcumin and sleep duration

Table 4. Association between curcumin treatment with sleep duration

| Changes in variable at baseline and after 6 weeks intervention | B         | Confidence interval 95% | p-value |
|---------------------------------------------------------------|-----------|-------------------------|---------|
| Daily nap (hr)                                                |           |                         |         |
| Curcumin-phospholipid complex (N=40)                          | -0.24     | -0.56 to 0.08           | 0.13    |
| Curcumin (N=40)                                               | -0.13     | -0.49 to 0.23           | 0.47    |
| Placebo (N=40)                                                |           |                         | Ref.1   |
| Nighty sleep (hr)                                             |           |                         |         |
| Curcumin-phospholipid complex (N=40)                          | 0.25      | -0.72 to 1.22           | 0.60    |
| Curcumin (N=40)                                               | -1.08     | -2.18 to 0.01           | 0.05    |
| Placebo (N=40)                                                |           |                         | Ref.1   |
| Total sleep (hr)                                              |           |                         |         |
| Curcumin-phospholipid complex (N=40)                          | -0.07     | -1.20 to 1.05           | 0.89    |
| Curcumin (N=40)                                               | -1.35     | -2.62 to -0.08          | 0.03    |
| Placebo (N=40)                                                |           |                         | Ref.1   |

General Linear Model was used after adjusting for, job, marital status, the number of family members, the head of the family, changes in the neutrophils, and serum lipoprotein (a) and adiponectin (26) at baseline and after 6 weeks intervention. Values are expressed as mean±SD for normally distributed data, and median and interquartile range for non-normally distributed data. Between groups comparisons were made by parametric statistical analysis for normally distributed data and nonparametric test for non-normally distributed data. BMI; body mass index.

Table 5. Correlation between sleep duration and PAB

| Variable                                      | PAB before (HK) | Changes in PAB at baseline and after 6 weeks intervention (HK) |
|-----------------------------------------------|----------------|----------------------------------------------------------------|
| Daily nap before (hr)                         | Spearman’s rho | p-value                                                          |
| Changes in daily nap at baseline and after 6  | -0.02          | 0.06                                                            |
| weeks intervention (hr)                       |                |                                                                  |
| Nighty sleep before (hr)                      | Spearman’s rho | p-value                                                          |
| Changes in nightly sleep at baseline and after| -0.11          | 0.23                                                            |
| 6 weeks intervention (hr)                     |                |                                                                  |
| Total sleep before (hr)                       | Spearman’s rho | p-value                                                          |
| Changes in total sleep at baseline and after 6| -0.11          | 0.23                                                            |
| weeks intervention (hr)                       |                |                                                                  |

PAB, prooxidant-antioxidant balance.

According to Tables 3 and 4, curcumin did not have significant effects on sleep duration (before and after adjusting for confounding factors) in overweight and obese subjects and total population, respectively (p>0.05).

As summarized in Table 5, there was no association between sleep duration and prooxidant-antioxidant balance before and after the intervention.

Discussion

To the best of our knowledge, this was the first clinical trial testing whether curcumin supplementation can affect sleep duration in subjects with MetS. One of the most important results was that all subjects suffered from short sleep duration (Table 1). An explanation for this finding can be obesity, because all subjects had MetS and their BMI were >30 kg/m². Several molecular mechanisms have been suggested to explain this observation (Shi et al., 2008). The short sleep duration can change the energy intake and expenditure balance (Spiegel et al., 1999), metabolic and endocrine function, leptin and ghrelin concentrations (Taheri et al., 2004), the adipocyte circadian clock (Shi et al., 2008), as well as the levels of insulin, cortisol, growth hormone and interleukin-6 that could contribute to metabolic dysfunction (Vgontzas et al., 2004; Taheri, 2006; Van Cauter et al., 1991).

In addition, our findings indicated that sleep duration was not affected by curcumin supplementation after 6 weeks of supplementation in subjects with MetS. It has been shown that autonomic,
neuroendocrine and immune system homeostasis can be regulated by sleep (McEwen, 2006; Moreira, 2006; Steiger, 2007). Insufficient sleep can disturb mental health and psychological balance. Poor sleep quality may also cause weight loss (McEwen, 2006; Cirelli, 2006; ), and behavioral changes (Obermeyer et al., 1991).

There is limited data on the effects of supplementation with curcuminoids and sleep quality in man. However, there are some related animal studies on sleep deprivation (Kumar and Singh, 2008; Noorafshan et al., 2017b; Pezze et al., 2016; Noorafshan et al., 2017b).

Kumar and Singh (2008) assessed the molecular mechanism of curcumin’s effects in improving sleep deprivation in male mice. Their results suggested that the curcumin’s positive effect on sleep behavioral alterations and oxidative damage was caused by the modulation of nitric oxide (Kumar and Singh, 2008). In rats, sleep deprivation can cause structural changes in the medial prefrontal cortex and produce memory impairment (Noorafshan et al., 2017b). The medial prefrontal cortex take vital innervations from the hippocampus and the brain stem (Pezze et al., 2016). Another animal study reported that curcumin can protect this area (Noorafshan et al., 2017b).

There is a relationship between sleep duration and prooxidant-antioxidant balance (Kumar and Singh, 2007). Sleep deprivation can augment the generation of free radicals and attenuation of antioxidative defense. We evaluated the curcumin’s effects on prooxidant-antioxidant balance in a previous study (Ghazimoradi et al., 2017). Our results did not show any effects in MetS patients. Moreover, in the current study, there was no association between sleep duration and prooxidant-antioxidant balance at baseline and after 6 weeks of supplementation. The results of this study do not support any significant effects of curcumin on sleep.

This was a sub-study of our previous double-blinded controlled trial on curcumin’s effects on CVD risk factors in subjects with MetS. It may have been better to assess sleep quality along with sleep duration using actigraphy for measuring sleep duration as a gold standard.

The results showed that sleep-duration was not affected by curcumin supplementation in MetS patients.

Acknowledgment

The authors would like to thank all participants collaborated in current study. Dr. Maryam Saberi-Karimian is a post-doctoral fellow of Mashhad University of Medical Sciences (MUMS), which her fellowship being granted by MUMS, Iran.

Conflicts of interest

The authors have declared that there is no conflict of interest.

References

Amirkalali B, Fakhrzadeh H, Sharifi F, Kelishadi R, Zamani F, Asayesh H, Saeid Safiri, Samavat T, Qorbani M. 2015. Prevalence of metabolic syndrome and its components in the Iranian adult population: a systematic review and meta-analysis. Iran Red Crescent Med J, 17: e24723.

Cirelli C. 2006. Cellular consequences of sleep deprivation in the brain. Sleep Med rev, 10: 307-321.

Fleiss JL. 2011. Design and analysis of clinical experiments, 3. John Wiley & Sons

Franco-Robles E, Campos-Cervantes A, Murillo-Ortiz BO, Segovia J, López-Briones S, Vergara P, Pérez-Vázquez V, Solís-Ortiz MS, Ramírez-Emiliano J. 2013. Effects of curcumin on brain-derived neurotrophic factor levels and oxidative damage in obesity and diabetes. Appl Physiol Nutr Metab, 39: 211-218.

Ghazimoradi M, Saberi-Karimian M, Mohammadi F, Sahebkar A, Tavallaie Sh, Safarian H, Ferns GA, Ghayour-Mobarhan M, Moohebati M, Esmaeili H, Ahmadinejad M. 2017. The effects of curcumin and curcumin–phospholipid complex on the serum pro-oxidant–
Curcumin and sleep duration

antioxidant balance in subjects with metabolic syndrome. Phytother Res, 31: 1715-1721.

Karalis DG. 2008. The Role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. Clin Cardiol, 3: 241-248.

Kumar A, Singh A. 2007. Protective effect of St. John’s wort (Hypericum perforatum) extract on 72-hour sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Planta Medica, 73: 1358-1364.

Kumar A, Singh A. 2008. Possible nitric oxide modulation in protective effect of (Curcuma longa, Zingiberaceae) against sleep deprivation-induced behavioral alterations and oxidative damage in mice. Phytomedicine, 15: 577-586.

Lee J, Park H. 2014. Relation between sleep duration, overweight, and metabolic syndrome in Korean adolescents. NMCD, 24: 65-71.

Marshall NS, Glozier N, Grunstein RR. 2008. Is sleep duration related to obesity? A critical review of the epidemiological evidence. Sleep Med Rev, 12: 289-298.

McEwen BS. 2006. Sleep deprivation as a neurobiologic and physiologic stressor: allostatic and allostatic load. Metabolism, 55: S20-S23.

Miquel J, Bernd A, Sempere T, Diaz-Alperi J, Ramirez A. 2002. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr, 34: 37-46.

Mirhosseini N-Z, Mohd Yusoff NA, Shahar S, Parizadeh SMR, Ghayour Mobarh M, Shakeriy MT. 2009. Prevalence of the metabolic syndrome and its influencing factors among adolescent girls in Mashhad, Iran. Asia Pac J Clin Nutr, 18: 131.

Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour Mobarhan M, Farns GA. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res, 27: 374-379.

Moreira T. 2006. Sleep, health and the dynamics of biomedicine. Social Sci Med, 63: 54-63.

Noorafshan A, Karimi F, Kamali A-M, Karbalay-Doust S, Nami M. 2017a. Restorative effects of curcumin on sleep-deprivation induced memory impairments and structural changes of the hippocampus in a rat model. Life sci, 189: 63-70.

Noorafshan A, Karimi F, Karbalay-Doust S, Kamali AM. 2017b. Using curcumin to prevent structural and behavioral changes of medial prefrontal cortex induced by sleep deprivation in rats. EXCLI J, 16: 510.

Obermeyer W, Bergmann BM, Rechtschaffen A. 1991. Sleep deprivation in the rat: XIV. Comparison of waking hypothalamic and peritoneal temperatures. Sleep 14: 285-293.

Panahi Y, Rahiminia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. 2014a. Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial. Phytother Res, 28: 1625-1631.

Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. 2014b. Adjutant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res, 28: 1461-1467.

Panahi Y, Sahebkar A, Amiri M., Davoudi SM, Beiraghdar F, Hoseiniejad SL, Kolivand M. 2012. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nut, 108: 1272-1279.

Pezze MA, Marshall H, Domonkos A, Cassaday HJ. 2016. Effects of dopamine D1 modulation of the anterior cingulate cortex in a fear conditioning procedure. Progres Neuro-Psychopharmacol Biol Psychiat, 65: 60-67.

Reaven GM. 1988. Role of insulin resistance in human disease. Diabetes, 37: 1595-1607.

Riemann D, Voderholzer U, Spiegelhalder K, Hornyak M, Bysse DJ, Nissen C, Nissen Ch, Hennig J, Perlis ML, Tebartz van Elst L, Feige B. 2007. Chronic insomnia and MRI-measured hippocampal volumes: a pilot study. Sleep, 30: 955-958.

Saberi-Karimian M, Parizadeh SMR, Ghayour Mobarhan M, Salahshooh MM, Dizaji BF, Safarian H, Javandoost A, Farns GA, Sahebkar A, Ahmadinejad M. 2018. Evaluation of the effects of curcumin in patients with metabolic syndrome. CCPA, 27: 555-563.

Sahebkar A. 2013. Why it is necessary to translate curcumin into clinical practice for...
the prevention and treatment of metabolic syndrome? Biofactors, 39: 197-208.
Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, Akhlaghi S, Ferns, GA Ghayour-Mobarhan M. 2013. Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res, 27: 1883-1888.
Sahebkar A PH, Pourghadamyari H, Moohebati M, Parizadeh SMR, Falsoleiman H, Dehghani M, Fazlinezhad A, Akhlaghi S, Tavallaie Sh, Paydar R, Ghayour-Mobarhan M, Ferns GA. 2011. A cross-sectional study of the association between heat shock protein 27 antibody titres, pro-oxidant-antioxidant balance and metabolic syndrome in patients with angiographically-defined coronary artery disease. Clin Biochem, 44: 1390-1395.
Sahoo DK, Roy A, Chainy GB. 2008. Protective effects of vitamin E and curcumin on L-thyroxine-induced rat testicular oxidative stress. Chem Biol Interact, 176: 121-128.
Shi Z, McEvoy M, Luu J, Attia J. 2008. Dietary fat and sleep duration in Chinese men and women. Int J Obes, 32: 1835-1840.
Spiegel K, Leproult R, Van Cauter E. 1999). Impact of sleep debt on metabolic and endocrine function. Lancet. 354: 1435-1439.
Steiger A. 2007. Neurochemical regulation of sleep. J Psychiatr Res, 41: 537-552.
Taheri S. 2006. The link between short sleep duration and obesity: we should recommend more sleep to prevent obesity. Arch Dis Child, 91: 881-884.
Taheri S, Lin L, Austin D, Young T, Mignot E. 2004. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med, 1: e62.
Taheri S. 2006. The link between short sleep duration and obesity: we should recommend more sleep to prevent obesity. Arch Dis Child, 91: 881-884.
Vasconcellos MT, Anjos LA. 2003. A simplified method for assessing physical activity level values for a country or study population. EJCN, 57:1025-1033.
Van Cauter E, Blackman JD, Roland D, Spire JP, Refetoff S, Polonsky KS. 1991. Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep. J Clin Invest, 88: 934-942.
Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, Chrousos. GP 2004. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metabol, 89: 2119-2212.
Visioli F, Davalos A. 2011. Polyphenols and cardiovascular disease: a critical summary of the evidence. Mini Rev Med Chem, 11: 1186-1190.
Zhang L, Zhang H-Q, Liang X-Y, Zhang H-F, Zhang T, Liu F-E. 2013. Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: role of oxidative stress, BDNF and CaMKII. Behav Brain Res, 256: 72-81.